Before Longevity Biotech 2025 kicks off, I sat down with Monty Montano to talk about my journey in aging research and how bridging academia and industry can drive progress in longevity science.

#LongevityBiotech #Aging #Epigenetics #Biotech #Healthspan #Research

I’ll explore how to reliably distinguish biological aging from technical noise, and why that matters for disease prediction & intervention.

Let’s connect if you’re into aging, biotech, translational research & longevity.

#LongevityBiotech #A4LI #Aging #Epigenetics #HealthTech #Biotech

New muscle-activating therapy could support healthier aging Atrogi’s oral candidate mimics exercise to preserve muscle, improve metabolism and counter GLP-1–linked muscle loss

New muscle-activating therapy could support healthier aging
Atrogi’s oral candidate mimics exercise to preserve muscle, improve metabolism and counter GLP-1–linked muscle loss.
#longevity #longevitybiotech

Semaglutide linked to reduced dementia risk in 1.7 million patients Real-world data suggest GLP-1 drugs like Ozempic may offer cognitive benefits beyond their metabolic applications.

Semaglutide linked to reduced dementia risk in 1.7 million patients
Real-world data suggest GLP-1 drugs like Ozempic may offer cognitive benefits beyond their metabolic applications.
#longevity #longevitybiotech #dementia

Coronary laser takes aim at calcified arteries in aging patients FastWave’s Sola IVL device completes first-in-human procedures as the company builds a two-pronged approach to vascular calcification.

Coronary laser takes aim at calcified arteries in aging patients
FastWave’s Sola IVL device completes first-in-human procedures as the company builds a two-pronged approach to vascular calcification.
#longevity #longevitybiotech

Metformin steps into the vascular aging spotlight New review explores metformin’s expanding potential in vascular health, geroscience and healthspan extension.

Metformin steps into the vascular aging spotlight
New review explores metformin’s expanding potential in vascular health, geroscience and healthspan extension.
#longevity #longevitybiotech

Engineered CAR immune cells show promise in Alzheimer’s CARs trained on Alzheimer’s antibodies can detect toxic tau and amyloid, raising the possibility of targeted, mobile brain cell therapies.

Engineered CAR immune cells show promise in Alzheimer’s
CARs trained on Alzheimer’s antibodies can detect toxic tau and amyloid, raising the possibility of targeted, mobile brain cell therapies.
#longevity #longevitybiotech #alzheimers

Single-gene rejuvenation target promises safer cell age reversal Shift Bioscience identifies potent, pluripotency-free alternative to OSKM, with implications for the future of cell rejuvenation therapeutics.

Single-gene rejuvenation target promises safer cell age reversal
Shift Bioscience identifies potent, pluripotency-free alternative to OSKM, with implications for the future of cell rejuvenation therapeutics.
#longevity #longevitybiotech #aging #FLFLondon2025 #FoundersForum

Telomir-1 shows systemic age-reversal in rare disease model Preclinical data suggest Telomir's oral drug may address multiple aging mechanisms including epigenetic drift and telomere shortening.

Telomir-1 shows systemic age-reversal effects in rare disease model
Preclinical data suggest Telomir’s oral drug may address multiple aging mechanisms including epigenetic drift and telomere shortening.
#longevity #longevitybiotech #aging

Rubedo doses first patient in trial targeting senescent skin cells RLS-1496 enters Phase 1 aiming to modulate GPX4 and reduce cellular senescence – could precision therapies for skin aging be on the horizon?

Rubedo doses first patient in trial targeting senescent skin cells
RLS-1496 enters Phase 1 aiming to modulate GPX4 and reduce cellular senescence – could precision therapies for skin aging be on the horizon?
#longevity #longevitybiotech #study #clinicaltrial

AI-designed compounds show promise in lifespan extension Polypharmacology meets machine learning as researchers harness AI to discover multi-target drugs that slow aging in worms.

AI-designed compounds show promise in lifespan extension
Polypharmacology meets machine learning as researchers harness AI to discover multi-target drugs that slow aging in worms.
#longevity #longevitybiotech #AI

From war wounds to longevity Petro Trush on turning wartime biotech into peacetime longevity innovation – and why Ukraine is poised to lead in healthy aging.

From war wounds to longevity
Petro Trush on turning wartime biotech into peacetime longevity innovation – and why Ukraine is poised to lead in healthy aging.
#longevity #longevitybiotech #longevityeconomy

'We’re really going to need cryopreservation' Tomorrow Bio CEO & Cofounder Emil Kendziorra on why cryopreservation could be our best hope when medicine can no longer save us.

‘We’re really going to need cryopreservation’
Tomorrow Bio CEO & Cofounder Emil Kendziorra on why cryopreservation could be our best hope when medicine can no longer save us.
#longevity #longevitybiotech #cryopreservation

A topical approach to slowing systemic signs of aging New data from a 12-week trial indicate that treating the skin may reduce inflammatory markers and slow biological aging processes.

A topical approach to slowing systemic signs of aging
New data from a 12-week trial indicate that treating the skin may reduce inflammatory markers and slow biological aging processes.
#longevity #longevitybiotech #supplements

M42 and Juvenescence collaborate on AI-enabled longevity drugs Abu Dhabi biotech collaboration aims to fast-track clinical-stage therapies that target the root mechanisms of aging and age-related disease.

M42 and Juvenescence collaborate on AI-enabled longevity drugs

Abu Dhabi biotech collaboration aims to fast-track clinical-stage therapies that target the root mechanisms of aging and age-related disease.

#longevity #longevitybiotech #longevityinvestment

Alnylam’s AMVUTTRA wins FDA nod for ATTR-related heart disease New RNAi therapeutic offers a novel mechanism to address both cardiomyopathy and polyneuropathy manifestations of the disease.

Alnylam’s AMVUTTRA wins FDA nod for ATTR-related heart disease
New RNAi therapeutic offers a novel mechanism to address both cardiomyopathy and polyneuropathy manifestations of the disease.
#longevity #longevitybiotech

Experimental drug shows promise in delaying early-onset Alzheimer's Study suggests anti-amyloid treatment may halve risk of cognitive decline in genetically predisposed individuals.

Experimental drug shows promise in delaying early-onset Alzheimer’s
Study suggests anti-amyloid treatment may halve risk of cognitive decline in genetically predisposed individuals.
#longevity #longevitybiotech

'Very early detection of cognitive decline is our purpose' Sens.ai Founder Paola Telfer on staving off cognitive decline and extending peak performance with transformative neurotechnology.

‘Very early detection of cognitive decline is our purpose’
Sens.ai Founder Paola Telfer on staving off cognitive decline and extending peak performance with transformative neurotechnology.
#longevity #longevitybiotech

Harnessing the power of personalized cell therapy Immorta Bio is developing autologous stem cell and immunotherapy solutions to combat aging and enhance cellular regeneration.

Harnessing the power of personalized cell therapy
Immorta Bio is developing autologous stem cell and immunotherapy solutions to combat aging and enhance cellular regeneration.
#longevity #longevitybiotech #cellularregeneration #stemcells